Loss of all or part of the long arm of human chromosome 5 is a recurrent abnormality in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), especially after chemotherapy for a prior malignancy. It is one of the worst prognostic indicators in AML, associated with chemotherapy resistance and short survival. These deletions center at band 5q31, which has thus been proposed as the location of a tumor suppressor gene; this site is to be distinguished from that observed in 5q-syndrome, centering at 5q32. To define the molecular extent and the clinical prevalence of 5q31 deletions, we collected a series of AML and MDS cases of mixed karyotype, taking care to exclude MDS cases with 5q-syndrome. The samples were analyzed for loss of heterozygosity (LOH) using a panel polymerase chain reaction (PCR)-based microsatellite markers from 5q. comparing malignant cells with normal tissue derived from lymphoblastoid cell lines or buccal mucosa scrapings. Losses were detected in seven of 29 matched samples, including four of 17 with MDS, and three of 12 with AML; six of these NTERSTITIAL LOSS of the long arm of chromosome 5, I del(5q), or complete loss of the entire chromosome, -5, is a well-recognized entity in malignant myeloid disorders, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).',' It is particularly frequent in leukemia that arises after previous treatment with chemotherapy, occurring in up to 50% of those cases. In this setting, there is considerable overlap between the diagnoses, as MDS is rapidly-transforming, and the AML may show features of a previous myelodysplastic ~t a t e .~.~ Del(5q) or -5 is less common in de novo AML, being seen in less than 10% of case^,^.^ but it is among the worst prognostic indicators. The response to chemotherapy is poor, with a complete remission rate of less than 30%, and a median survival of 4 These myeloid disorders share several common features, including trilineage involvement, pronounced dysplasia, and characteristic megakaryocytic abnormalities. Additional cytogenetic abnormalities are frequent, with the most common being del(7q) or -7.
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In contrast to these aggressive malignancies, the 5q-syndrome is a milder form of myelodysplasia in which refractory anemia is the predominant clinical feature.' Characteristically, the chromosome 5 deletion is the sole cytogenetic abnormality. The course is indolent, and progression to acute leukemia is uncommon.
The consistent occurrence of chromosome 5 deletions in myeloid disorders suggests the presence of a tumor suppressor gene, which is important to hematological transformation. To localize this gene, we and others have attempted to define a consistently deleted region, using cytogenetic and molecular methods to map the extent of deletions in clinical samples.
Our cytogenetic studies specified the interleukin-9 (IL-9)-D5S166 interval at 5q3l1O in MDS and AML, consistent with that reported el~ewhere,'*~~~ while the 5q-syndrome has been mapped to a more distal interval at 5q32" and thus appears to be linked to a different gene.' seven also had a cytogenetically-visible del(5q) or -5. The one case without a cytogenetic deletion showed molecular loss of three contiguous markers, with retention of flanking markers interleukin-9 (IL-9) and D5S414, and thus contained a small deletion that is below cytogenetic resolution. PCR failed to detect 5q loss in two cases with large cytogenetic deletions, but both had been treated and contained low percentages of malignant cells in the samples. This study thus led to the identification of a case with a minimal deletion for the 5q31 tumor suppressor gene, specified by IL-9-D5S414, that is approximately 1 Mb (2 cM) in extent. Additionally, we demonstrate that PCR-based allelotyping is a reliable method for the detection of chromosomal deletion in myeloid malignancy, providing the specimens contain a high proportion of malignant cells. These studies will help to identify the tumor-suppressor gene at 5q31, and will help to develop molecular methods for diagnosis and monitoring of these disorders.
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In this study, we attempted to further refine the localization of the del(5q) gene at 5q31, by investigating clinical samples of AML and MDS (excluding 5q-syndrome), using a panel of polymerase chain reaction (PCR)-formatted microsatellite markers within the IL-9-D5S 166 interval. Losses were detected by comparing malignant cells with normal tissue from the same individuals, derived from lymphoblastoid cell lines or buccal mucosa scrapings. Our series, reported here, defines a minimal deletion of approximately 2 cm bounded by the markers IL-9 and D5S414. Additionally, we demonstrate that PCR-based allelotyping is a reliable method for the detection of chromosomal deletion in myeloid malignancy. These studies will help us to identify the tumorsuppressor gene that is implicated in del(5q), and will help to develop molecular markers for diagnosis, prognosis, and treatment of these disorders.
MATERIALS AND METHODS
Clinical samples. Bone marrow or peripheral blood was obtained as part of routine clinical management of patients with AML and MDS, followed at the University of Chicago Hospitals and Loyola University Medical Cancer. Informed consent was obtained. All patients who received induction therapy for AML were treated on standard protocols containing cytosine arabinoside and daunomycin, while supportive care was performed on an ad hoc basis, including blood products and growth factors. Clinical information and karyotype was obtained from the patient's medical history.
Self-collection of buccal smears was done with sterile cytology brushes (Scientific Products #S7766-1A; McGaw Park, IL). The patient was instructed in the procedure of brushing the inside of the cheek (both sides) by twirling the brush on the inner cheek for 30 seconds. Two samples from each patient were collected. The brush is inserted back into the sterile sleeve, tightly sealed, and stored at 4°C until used.
Establishment of Epstein-Barr virus-transformed lymphoblaszoid cell lines. Peripheral blood for Epstein-Barr virus (EBV) transformation was obtained only from University of Chicago patients, after obtaining informed consent. In most cases, the sample was obtained from a patient during active disease rather than at remission. The method has been described previously. '5 DNA was prepared from buccal smears using a modification of the method described by Richards et al." A total of 0.6 mL of 50 mmol/L NaOH (sterile) is added into a 3-mL tube containing a brush that has been clipped to fit inside the tube, and the tube is vortexed for 30 seconds. The tube still containing the brush is then heated to 95°C for 5 minutes and vortexed again. The brush is carefully removed, leaving behind any residual liquid, and 0.06 mL of 1 mmol/L Tris pH 8.0 (sterile) is added, and the sample vortexed for 10 seconds. DNA is stored at 4°C and .002 mL is used for each PCR reaction. High-molecular-weight DNA was isolated from lymphoblasts, bone marrow, or peripheral blood by sodium dodecyl sulfate (SDS)/Proteinase K digestion followed by phenol extraction and ethanol pre~ipitation.'~ PCR reactions were performed on 0.1 pg of sample DNA or 0.005 mL of buccal smear extract, using the following conditions: 10 mmol/L Tris-HCI, pH 8.0,50 mmoVL KC1, 1.5 mmol/L MgC12, 200 pnoVL dATP, dGTP, and d'ITP, 50 pmolL dCTP, 1 j K i a 32P dCTP (3,000 Cihmol), 5% glycerol, 0.1% Triton X-100, 0.5 U Taq polymerase (Perkin Elmer-Cetus, Foster City, CA) and 100 ng of each primer in a 20-pL reaction. The reactions were run in a Perkin Elmer model 480 temperature cycler using these parameters: denaturing at 94°C for 3 minutes, then 35 cycles of 94°C (40 seconds), 55°C (30 seconds), and 72°C (30 seconds), with a final extension of 72°C for 5 minutes. One to five microliters of each PCR reaction was separated on an 8 molL urea 6% polyacrylamide gel and exposed to x-ray film. Loss of heterozygosity (LOH) was scored visually, comparing the intensity of the microsatellite bands obtained from the malignant with the normal cells.
DNA preparation.
PCR analysis with microsatellite markers.
RESULTS
Selection of polymorphic markers for the study. The short-tandem repeat markers used in this study are given in Table 1 , listed in order from the most centromeric to the most telomeric.'"22 The markers were selected for this study based on their high heterozygosity values, their location within the IL-9-D5Sl66 interval at 5q31, (D5S816 to D5S500) or flanking it (D5S806, DSSSOS), and an unambiguous determination of the position of the marker relative to other markers. Marker order was established by reference to several comprehensive genetic and physical maps, ' x~' y~2 1 , 2 2 confirmed by our analysis of a series of overlapping YACs; the description of the YAC contig will be published elsewhere. The markers at 5q31 span approximately 5 cM.
The use of these markers on the diagnostic specimen resulted in a strong PCR signal. When a deletion was present, the sample usually showed a clear allelic loss with little residual normal allele when compared with the normal DNA, suggesting a high proportion of malignant cells was present in the sample. The early samples were compared with EBVtransformed lymphocytes obtained from the patient's blood, as a source of normal DNA; however, the buccal smear method was later adopted because of its ease and low cost. We were able to obtain both buccal cell DNA and lymphoblastoid DNA for two cases on this study and found that identical results were obtained in both cases (Fig 1) . The success rate for generating interpretable signals for buccal DNA is nearly 100% and provides sufficient material for several hundred PCR analysis. In all, we have analyzed 27 buccal samples collected from AMLMDS patients, 14 reported on this study, and we have had only two failures. In both failed samples, particulate contamination was found in the sample, which could usually be traced to contamination at the time of sample collection. In all, buccal samples have been collected from in excess of 50 either patients or normal controls, and polymorphic alleles are always represented at normal ratios. These methods were applied to 29 matched samples collected from patients with AML and MDS. To avoid confusion between the 5q31 and 5q32 deletions, care was taken to exclude MDS cases with a clinical diagnosis of 5q-syndrome., All patients were adults, ranging in age from 25 to 85 years, with an average age of 59. It should be stressed that this was not a prospective, unselected series, as an attempt was made to include cases with known del(5q) to verify the method, and patients were sampled at various stages during the course of their treatment. A summary of the clinical features of the study population is given in Table 2 .
There were 17 cases of MDS, with or without progression to AML, with an average age of 63 (Table 2) . Three MDS cases were considered to be therapy-related (t-MDS), as they arose following treatment for other malignancies: Case no. 6 followed Hodgkin's disease treated with chemotherapy; case no. 9 followed prostate cancer treated with radiation therapy; case no. 12 followed endometrial cancer treated with radiation therapy. The majority of cases, 12 of 17, progressed to AML, including all of the t-MDS cases. Eleven cases received induction therapy for AML, and only four (36%) achieved a complete remission (CR); there were no long-term survivors among this group (data not shown).
There were 12 cases of AML which arose de novo, without a prior history of MDS, with an average age of 54 (Table  2) . Eleven received induction therapy, with seven complete responders (64%), and four long-term survivors (data not shown). Results of PCR analysis.
For case no. 24, had a molecular deletion with no apparent cytogenetic loss of chromosome 5. Review of case no. 24 shows a patient who presented to our institution in first relapse, 5 months after treatment for AML at another institution. At presentation, his white blood cell (WBC) count was 104,000, and his blasts showed M5A morphology and cytochemistry; his presenting bone marrow and cytogenetic results were not available to us. His karyotype showed t(6;11), del (7) (q31q36), + 18, but there were no abnormalities of chromosome 5. The PCR test showed deletion of only three of seven informative markers within 5q3 I, and none of the two flanking markers (Figs 2 and 3) . Thus, the chromosome 5 deletion in this case appears to encompass only a fraction of band 5q3 1.1, and is, therefore, below the limits of cytogenetic detection by standard light microscopy. The clinical course of this patient is typical for del(5q) leukemia, with a brief remission duration, and survival of less than I O months.
The coincidental presence of del(7q) in this case is also typical for a del(5q) malignancy, as these two abnormalities frequently associate." In this regard, it is interesting that a total of seven cases in our series showed a cytogenetic del (7) or -7 including two with MDS and four with AML; of these seven, five also had cytogenetic and/or molecular evidence of chromosome 5 deletion.
There are two cases with a cytogenetic del(5q) that were not detected by this PCR method. Both had large deletions, encompassing 5q13 to 5q33, and most of the markers were informative on these cases. On review, both patients had been partially treated, and the specimens that were obtained Abbreviations: MDS, myelodysplasia; t-MDS, therapy-related-myelodysplasia (arising after cytotoxic chemotherapy); AML, acute myeloid leukemia; t-AML, acute myeloid leukemia arising after cytotoxic chemotherapy for other cancer; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation.
*The complete karyotype is not given; only the abnormal findings are listed.
t Percent of total metaphases which carry a chromosome 5 abnormality -5, del(5q). or dic(5) when one is detected.
* Loss, loss of heterozygosity of at least one informative marker; no loss, no loss of heterozygosity detected in any informative marker.
MDS progressed to AML.
contained less than 6% malignant cells. The failure to detect LOH is due to the presence of normal cells, which contribute signal to the lost allele. In our experience, LOH can usually be unambiguously assigned when the sample contains no more than 40% normal cells; this is similar to the experience of Kroef et al.23 This reinforces the need to insure that the test specimen is adequately enriched for malignant cells, preferably using a pretreatment sample. A comparison of the extent of deletion for the seven cases with LOH is given in Fig 3. The deletion map is consistent with the cytogenetic findings, showing interstitial deletions with retention of (or uninformative) flanking markers (nos . 5 , 12,24, 25) . a large deletion encompassing flanking marker (no. 13) or complete chromosomal loss (no. 20). Interestingly, case no. 6, which shows a dicentric 5, dic (5; 17)(qll;pl I), shows complete loss of all of the markers tested, consistent with the near complete loss of the long arm.
Deletion map.
As shown above, case no. 24 had a small deletion detected by only three markers (AFM350yb1, D5S1372, and D5S476), with retention of flanking markers IL-9 and D5S414. A deletion this small includes only a fraction of a chromosomal band, and is not likely to be cytogenetically visible. Case two thus defines a minimal deletion interval for the tumor suppressor gene involved in (del)5q.
DISCUSSION
The study presented here demonstrates the detection of chromosome 5 deletions in AML and MDS by means of PCR-based allelotyping and contributes further to the localization of the 5q31 tumor suppressor gene by identiying a case with a small deletion at IL-9-D5S414. The case containing this loss has a clinical picture that is typical of other cases with 5q31 deletions, including the presence of a del(7q). A size estimate for this interval is based on the recently published Cooperative Human Linkage Center (CHLC) map, showing that the genetic distance between D5S393-D5S414 is 2 cM. We estimate that the physical extent of the interval is no greater than 1,000 kb, based on the size of several overlapping YACs, which cover this interval (Horrigan and Westbrook, unpublished data). This localization will greatly facilitate the identification of the presumed tumor suppressor gene that is implicated in del(5q) myeloid malignancies.
Recently, Fairman et all' reported the loss of two polymorphic markers in a patient sample carrying a t(5; 18; 17) (q3 1 ;PI 1 ;q I 1 ); one of the markers (D5S399) is also included in our minimal deletion interval. As Fairman et al did not report any retained flanking markers, it is impossible to correlate the extent of their deletion with ours, but it does reinforce the localization of this gene to 5q3 1.
Because our clinical series is neither prospective nor unselected, it is not possible to draw conclusions about the incidence or clinical outcome of MDS and AML associated with del 5q. Nevertheless, the series illustrates several important features about these myeloid malignancies, which have been noted elsewhere.'.".'' First of all, it represents a significant fraction of therapy-related leukemia; here, two of three such cases had a del (5) . It is frequent in MDS. where it usually progresses to AML. In de novo AML, it can appear in any FAB subtype, though it is usually not the only abnormality. Associations with del(7q) or -7 are frequent, reinforcing previous suggestions that loss of presumed tumor-suppressor genes from both chromosomal regions might have a synergistic effect on transformation or disease progression. Del(5q) tends to occur in an older age group; there was only one patient in this group with cytogenetic or molecular del(5q) who was under age 45, and most were over 50. The outcome of treatment of del(5q) AML is poor, remissions are infrequent and short-lived, and long-term survivors are rare.
Our study demonstrates the feasibility of molecular detection of chromosomal deletions for clinical diagnosis in AML and MDS. In most of our cases, the diagnostic sample contained a high proportion of malignant cells, such that LOH was unambiguous; in cases that had been partially treated, however, LOH could not be unambiguously assigned if the fraction of normal cells was too high. This finding underscores the need for pretreatment samples for this test; alternatively, cell fractionation methods might be used to separate malignant from normal cells."." This finding also suggests a potential use for this PCR method as means to monitor treatment and demonstrate repopulation of the marrow with normal elements.
Finding an appropriate sample of normal tissue for comparative analysis has been the limiting step in the use of For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From molecular methods for deletion analysis in hematological malignancies. Previous studies relied on the use of remission samples, allelic imbalance, EBV-transformed lymphocytes, or fractionation of the sample in lymphocyte (normal) and myeloid (malignant) population^.'^.^^.^^,^^ All of these approaches are problematic or require excessive sample manipulation. In particular, a study using mouthwash samples found they were unsuitable for deletion analysis by microsatellites, due to significant contamination with polymorphonuclear ~e l l s . 2~ In contrast, our study shows that a simple scraping of buccal mucosa provided enough DNA for more than 100 PCR reactions and was easily collected and transported, with minimal sample handling.
We demonstrated that the detection of 5q LOH by this method is comparable to cytogenetic detection, and indeed may improve sensitivity, as it permits the analysis of samples with inadequate cytogenetics, and allows for the detection of submicroscopic deletions. Care must be taken to use samples containing a low proportion of normal cells so as not to mask the detection of the deletion allele. A larger scale clinical trial of this method is warranted to investigate the incidence and clinical significance of submicroscopic deletions of chromosome 5 in myeloid malignancies.
